

## AMENDMENTS TO THE SPECIFICATION

Please amend the TITLE as follows:


### EXCR3 ANTAGONISTS SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES AND METHODS FOR THEIR USE

Please amend the first paragraph of the specification that directly follows the title as follows:

*B1*  
This application claims the benefit of U.S. Provisional applications Serial Nos. 60/255,241, filed December 11, 2000 and application Serial No. 60/296,499, filed June 6, 2001, the disclosures of each being disclosure of which is incorporated herein by reference.

Please amend the ABSTRACT OF THE DISCLOSURE as follows:

*B2*  
Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the Compounds having the formula:



wherein A<sup>4</sup> is N and X is -C(O)- or -CH<sub>2</sub>-, are provided, which are useful as modulators of a chemokine receptor and for treatment of inflammatory and immunoregulatory disorders and diseases. Pharmaceutical compositions and methods of using these compounds for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes, are also provided.